• Decrease font size
  • Default font           size
  • Increase font size
Prosonix CEO David Hipkiss talks to in-Pharma PDF Print E-mail
Wednesday, 17 March 2010 00:00
David Hipkiss, CEO of Prosonix, recently spoke to in-Pharma technologist.com about the company's recent launch of its new UMAX® particle engineering technology and how it is set to revolutionise the field of respiratory medicines.  Please see http://www.in-pharmatechnologist.com/Processing-QC/Prosonix-launches-UMAX-particle-tech-for-respiratory-drugs For further details of the potential of UMAX® particles in delivering better medicines for respiratory illness and disease please see the technology article on UMAX® and technology launch news item: Prosonix Announce The Launch Of UMAX technology

 

Last Updated on Monday, 26 September 2011 22:23
 

Latest News

03 Feb 2012 - Geoff Down appointed as Chief Medical Officer
Prosonix Appoints Respiratory Drug Development Expert Dr Geoff Down as Chief Medical Officer Prosonix (Oxford, UK), an emerging pharmaceutical company developing a portfolio of enhanced respiratory...
More in: Latest

Events

Respiratory Drug Delivery 2012
10 October 2011 08:57
article thumbnai